Clinical trial NCT00418236: Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
Official title: Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-01-04
Enrollment: 400
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 63
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE

Brief summary: It has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense. However, while breast density may be a risk factor, the etiology of the relationship between breast cancer and breast density is not understood. Furthermore, it is well recognized that breast cancer can still develop in women whose breasts are not dense.

At menopause, the amount of breast glandular tissue and stroma naturally decreases due to a lack of hormonal stimulation. This is characterized as a decrease in the mammographic density. Although certain medications, including hormone therapy (HT) and dopamine antagonists can increase breast density, these effects are reversible upon discontinuation of the specific agent. Other medications such as the selective estrogen receptor modulators (SERM), raloxifene (RAL) and tamoxifen, have been shown to not affect breast density and allow the normal age-related changes to occur. The effects of bazedoxifene (BZA), a new SERM, on breast density are not known. The purpose of this study is to examine the effect of BZA on breast density changes over 24 months in postmenopausal women. The results may be useful for clinicians to understand the effect of BZA on breast density and its mammographic effects.

This is an observational, multicenter, double-blind, randomized, placebo- and active comparator-controlled study. It is also an ancillary that will use women who are already participants in a phase 3 trial for fracture reduction (protocol 3068A1-301-WW; primary study). In the primary study, subjects received BZA 20 mg, BZA 40 mg, RAL 60 mg, or placebo. This ancillary study will request a subset of participants to use their mammograms taken in this study. Their mammogram will be digitized by a central imaging center. A single radiologist will perform the quantifications of breast density from the digitized mammograms.


Eligibility criteria: 1. Each subject must have participated or is currently participating in study 3068A1 301, and must satisfy all of the following criteria
2. Has completed 24 months of treatment.
3. Had a mammogram at the baseline visit and at the month 24 visit, and both are original films that are technically acceptable for reading.
4. Was less than or equal to 62 years of age at the time of study randomization in the primary study.
5. Was at least 80% compliant with test article administration.
6. Did not take any medications 6 months prior to screening in the primary study or during the first 24 months of the study that could cause a change in breast density.
7. Was enrolled at a site that has at least 4 subjects meeting all of the above inclusion criteria.
8. Was enrolled at a clinical site that is still participating in the primary study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
state: California
city: Upland
country: United States
state: California
city: Meridian
country: United States
state: Idaho
city: Brooklyn Center
country: United States
state: Minnesota
city: Billings
country: United States
state: Montana
city: Bozeman
country: United States
state: Montana
city: Bismark
country: United States
state: North Dakota
city: Fargo
country: United States
state: North Dakota
city: Jamestown
country: United States
state: North Dakota
city: Watertown
country: United States
state: South Dakota
city: Buenos Aires
country: Argentina
city: Sorocaba
country: Brazil
state: Sao Paulo
city: Goiania
country: Brazil
city: Mato Grosso
country: Brazil
city: Sofia
country: Bulgaria
city: Sofia
country: Bulgaria
city: Vancouver
country: Canada
state: British Columbia
city: Winnipeg
country: Canada
state: Manitoba
city: Quebec City
country: Canada
state: Quebec
city: Sherbrooke
country: Canada
state: Quebec
city: Santiago
country: Chile
city: Zadar
country: Croatia
city: Zagreb
country: Croatia
city: Vejle
country: Denmark
city: Tallin
country: Estonia
city: Tartu
country: Estonia
city: Agarismo
country: Mexico
city: Amsterdam
country: Netherlands
city: Krakow
country: Poland
city: Warszawa
country: Poland
city: Bucharest
country: Romania
city: Cluj-Napoca
country: Romania
city: Iasi, Jud. Iasi
country: Romania
city: Johannesburg
country: South Africa
city: Parow
country: South Africa
city: Pretoria
country: South Africa
city: Somerset West
country: South Africa
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
affiliation: For Bulgaria, WVPIMED@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Croatia, WPBUMED@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Denmark, medinfonord@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Estonia, WVPMED@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Netherlands, trials-NL@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Poland, WPWZMED@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Romania, WVPIMED@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For South Africa, ZAFinfo@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Canada, clintrialparticipation@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Mexico, gomezzlj@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Argentina, Scheima@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Chile, scheima@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
affiliation: For Brazil, xavierl@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
References: